Table 1. Characteristics of IIV4-cc studies included in the systematic review.
| Study | Design (vaccine) | Study population | Outcomes |
|---|---|---|---|
| DeMarcus et al. (2019) | • Test-negative case-control • 2017–2018 influenza season • (IIV4-cc versus egg-based IIV4) |
• US DOD healthcare beneficiaries six months–94 years of age • 1,757 cases (laboratory-confirmed): • 531 vaccinated; IIV4-cc (n=192), egg-based IIV4 (n=339) • 2,280 controls: • 977 vaccinated; IIV4-cc (n=314), egg-based IIV4 (n=663) |
• VE against laboratory-confirmed influenza • OR for individuals vaccinated with cell-derived vaccine compared to egg-derived vaccine |
| Izurieta et al. (2018) | • Retrospective cohort • 2017–2018 influenza season • (IIV4-cc vs egg-based IIV4-SD, egg-based IIV3-SD, IIV3-adj, IIV3-HD) |
• Medicare beneficiaries 65 years of age and older • IIV4-cc (n=653,099) • Egg-based IIV4-SD (n=1,844,745) • Egg-based IIV3-SD (n=8,449,508) • IIV3-adj: (n=1,465,747) • IIV3-HD (n=1,007,082) |
• rVE for influenza-related health care interactions |
| Boikos et al. (2018) NCT01992094 |
• Retrospective cohort • (IIV4-cc vs egg-based IIV4) • 2017–2018 influenza season |
• EMR of US patients four years of age or older • IIV4-cc (n=92,192) • Egg-based IIV4 (n=1,255,983) |
• Propensity-score matched rVE against ILI |
| Klein et al. (2018) | • Retrospective cohort • 2017–2018 influenza season • (IIV4-cc vs egg-based IIV) |
• Kaiser Permanente members 4–64 years of age • IIV4-cc (n=932,874) • Egg-based IIV (n=84,440) |
• rVE against laboratory-confirmed influenza A(H3N2) • rVE against all laboratory-confirmed influenza |
| Bart et al. (2016) |
• RCT • 2013–2014 influenza season • (IIV4-cc vs IIV3-cc) |
• Healthy adults 18 years of age and older • IIV4-cc (n=1,335) • IIV3-cc, B/Yam (n=676) • IIV3-cc, B/Vic (n=669) |
• GMT ratio 22 days post-vaccination • Seroconversion rate three weeks (day 22) post-vaccination • HI antibody response • Seroprotection rate • Solicited AEs within seven days of vaccination • Unsolicited AEs (day 1–22 post-vaccination) |
| Hartvickson et al. (2015) NCT01992107 |
• RCT • 2013–2014 influenza season • (IIV4-cc vs IIV3-cc) |
• Healthy children 4–18 years of age; stratified into two age cohorts: 4–9 years of age and 9–18 years of age • IIV4-cc (n=1,159) • IIV3-cc, B/Yam (n=593) • IIV3-cc, B/Vic (n=581) |
• GMT ratio 22 days post-vaccination • Seroconversion rate three weeks (day 22) post-vaccination with last dose • Seroprotection rate • Solicited AEs within seven days of vaccination • Unsolicited AEs (within 22 days of vaccination) |
Abbreviations: AE, adverse event; EMR, Electronic medical record; GMT, geometric mean titre; HI, hemagglutination inhibition; IIV, inactivated influenza vaccine; IIV3, trivalent inactivated influenza vaccine; IIV3-adj, adjuvanted trivalent inactivated influenza vaccine; IIV3-cc, cell-culture based trivalent inactivated influenza vaccine; IIV3-HD, high-dose trivalent inactivated influenza vaccine; IIV3-SD, standard-dose trivalent inactivated influenza vaccine; IIV4, quadrivalent inactivated influenza vaccines; IIV4-cc, cell-culture based quadrivalent inactivated influenza vaccine; IIV4-SD, standard-dose quadrivalent inactivated influenza vaccine; ILI, influenza-like illness; NCT, National clinical trial number; OR, odds ratio; RCT, randomized controlled trial; rVE, relative vaccine effectiveness; US DOD, United States Department of Defense; VE, vaccine effectiveness